ORKA vs. OCUL, IDYA, BLTE, ANIP, DNLI, BEAM, GLPG, RXRX, AGIO, and IRON
Should you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Ocular Therapeutix (OCUL), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), ANI Pharmaceuticals (ANIP), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Galapagos (GLPG), Recursion Pharmaceuticals (RXRX), Agios Pharmaceuticals (AGIO), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.
Oruka Therapeutics vs. Its Competitors
Ocular Therapeutix (NASDAQ:OCUL) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.
Ocular Therapeutix currently has a consensus price target of $17.83, suggesting a potential upside of 41.99%. Oruka Therapeutics has a consensus price target of $42.00, suggesting a potential upside of 175.05%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Ocular Therapeutix.
In the previous week, Oruka Therapeutics had 15 more articles in the media than Ocular Therapeutix. MarketBeat recorded 19 mentions for Oruka Therapeutics and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.93 beat Oruka Therapeutics' score of 0.75 indicating that Ocular Therapeutix is being referred to more favorably in the media.
59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Oruka Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ocular Therapeutix has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500.
Oruka Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Oruka Therapeutics' return on equity of -26.26% beat Ocular Therapeutix's return on equity.
Summary
Oruka Therapeutics beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.
Get Oruka Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oruka Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ORKA) was last updated on 9/25/2025 by MarketBeat.com Staff
Free ORKA Stock Alerts